ADCs Transform NSCLC Treatment Landscape with Multiple FDA Approvals and Expanding Clinical Applications
核心洞察
Antibody-drug conjugates (ADCs) have emerged as a transformative class of therapies in non-small cell lung cancer, combining the precision of monoclonal antibodies with potent cytotoxic payloads to create targeted treatment options.
Multiple ADCs have received FDA accelerated approval for NSCLC (搜索) treatment, including trastuzumab deruxtecan for HER2 (搜索)-mutant disease, telisotuzumab vedotin for high c-Met (搜索) overexpression, and datopotamab deruxtecan for pretreated EGFR (搜索)-mutant NSCLC.
Despite promising clinical results, ADCs face ongoing challenges including target selectivity issues, on-target off-tumor toxicity, resistance mechanisms, and the need for optimal combination strategies with other therapies.
Antibody-drug conjugates (ADCs) have emerged as one of the most significant therapeutic innovations in non-small cell lung cancer (NSCLC (搜索)) treatment, fundamentally changing the treatment paradigm for both biomarker-selected and biomarker-agnostic disease. These sophisticated agents combine the precision targeting of monoclonal antibodies with the potent cytotoxic activity of chemotherapy payloads, offering new hope for patients who have exhausted traditional treatment options.
At the 2025 World Conference on Lung Cancer in Barcelona, Spain, Dr. Giannis Mountzios from the Henry Dunant Hospital Center in Athens provided comprehensive insights into how ADCs are reshaping NSCLC (搜索) treatment approaches. The technology represents a new way of delivering chemotherapy with improved pharmacokinetics and continuous tumor cell exposure compared to traditional free chemotherapy administration.
Structural Innovation Drives Therapeutic Precision
ADCs are engineered from three critical components that work in concert to deliver targeted cancer therapy. The antibody component, typically an IgG1 monoclonal antibody, provides high target specificity while its Fc gamma domain engages immune effector mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and complement activation, conferring intrinsic anticancer properties independent of the payload.
The linker component plays a crucial role in determining pharmacodynamic and pharmacokinetic properties. As Dr. Mountzios explained, linkers can be either cleavable, allowing payload release outside cancer cells within the tumor microenvironment, or noncleavable, restricting payload release to intracellular compartments only.
The payload provides the cytotoxic activity through highly potent small molecules that typically disrupt DNA structure or tubulin polymerization to induce apoptosis. These payloads generally fall into three categories: antimicrotubule agents such as auristatins and maytansinoids, DNA-cleaving agents such as calicheamicins, and topoisomerase inhibitors such as camptothecins.
Next-Generation ADC Technologies
The ADC landscape has rapidly diversified beyond the classic three-component structure. Emerging technologies include bispecific and biparatopic ADCs that can target two different antigenic epitopes either on the same cell or different cells. Prodrug antibody conjugates carry peptide masks that protect payloads from release outside the tumor microenvironment, allowing controlled release through enzyme-dependent or pH-dependent mechanisms.
Additional innovations include immune-stimulating ADCs, protein-degrader ADCs that act through ubiquitination and proteasome degradation of target proteins, and dual-drug ADCs capable of carrying two different payload types on the same conjugate.
Clinical Success Stories and Regulatory Milestones
Several ADCs have achieved FDA accelerated approval for NSCLC (搜索) treatment, demonstrating the clinical potential of this therapeutic class. Trastuzumab deruxtecan (T-DXd, Enhertu) received approval on August 11, 2022, for HER2 (搜索)-mutant NSCLC after prior systemic therapy, supported by the DESTINY-Lung02 trial which demonstrated objective response rates exceeding 50% and median overall survival approaching 18 months.
Telisotuzumab vedotin (Emrelis (搜索)) gained accelerated approval on May 14, 2025, for patients with high c-Met (搜索) protein overexpression (≥50% of tumor cells with strong [3+] staining) after prior systemic therapy, following encouraging results from the LUMINOSITY trial. On June 23 of the same year, datopotamab deruxtecan (Dato-DXd, Datroway) received approval for pretreated EGFR (搜索)-mutant NSCLC (搜索) based on pooled analyses from TROPION-Lung05 and TROPION-Lung01 trials, which reported an objective response rate of 43% and median overall survival of 15.6 months.
Payload Design Determines Therapeutic Properties
The payload component often dictates both therapeutic potency and toxicity profiles. Dr. Mountzios compared payload design to aerospace engineering, where spacecraft size and orbital behavior are determined by cargo weight. Similarly, ADC molecular behavior and pharmacokinetic properties are defined by payload characteristics.
This principle is illustrated by comparing two anti-TROP2 (搜索) ADCs: sacituzumab govitecan (Trodelvy), which uses the irinotecan metabolite SN-38, and datopotamab deruxtecan, which employs a deruxtecan payload approximately 10-fold more potent. Small differences in drug-to-antibody ratios further distinguish these agents, contributing to meaningful variations in clinical efficacy and safety profiles.
Biomarker-Driven vs. Agnostic Approaches
ADCs can be categorized as either biomarker-selected or biomarker-agnostic therapies. Biomarker-selected ADCs require specific biomarker presence or overexpression for clinical efficacy, exemplified by telisotuzumab vedotin for MET overexpression and trastuzumab deruxtecan for HER2 (搜索) mutations and protein expression.
In contrast, biomarker-agnostic ADCs demonstrate efficacy across broader patient populations with outcomes less dependent on biomarker levels. TROP2 (搜索)-targeting ADCs and HER3 (搜索)-targeting ADCs, such as patritumab deruxtecan (HER3-DXd (搜索)), fall into this category. This distinction significantly influences patient selection strategies and therapeutic applicability breadth.
Emerging Clinical Evidence
Sacituzumab tirumotecan represents one of the latest ADC additions, demonstrating promising results in the phase 2 OptiTROP-Lung03 trial. Patients with pretreated EGFR (搜索)-mutant NSCLC (搜索) randomized to receive sacituzumab tirumotecan achieved median progression-free survival of 6.9 months compared with 2.8 months for docetaxel. Objective response rates were significantly higher with the ADC, and overall survival benefits remained evident even after accounting for crossover in more than one-third of patients.
These data led to sacituzumab tirumotecan approval in China in March 2025 for pretreated EGFR (搜索)-positive NSCLC (搜索), highlighting how novel ADCs can extend treatment options for patients with specific molecular subsets who have exhausted other targeted therapies.
Persistent Clinical Challenges
Despite significant advances, ADCs face ongoing challenges that require continued innovation. Target selectivity and specificity remain critical, as imperfect targeting can result in off-tumor effects. On-target, off-tumor toxicity is particularly concerning when target antigens are expressed at low levels in normal tissues.
Resistance mechanisms, including antigen expression downregulation, altered trafficking, or drug efflux, can limit response durability. As Dr. Mountzios noted, key remaining challenges include improving target selection, identifying robust biomarkers, reducing notorious on-target off-tumor toxicity, and determining optimal settings and sequences for combination therapies.
Combination Strategy Development
ADCs are being evaluated in combination with immune checkpoint inhibitors, chemotherapy, and tyrosine kinase inhibitors. However, balancing enhanced efficacy with overlapping toxicity risks, such as pneumonitis, remains a pressing clinical concern. Data from trials like FLAURA2 and MARIPOSA have demonstrated that intensified regimens can lead to improved outcomes, particularly in EGFR (搜索)-mutated NSCLC (搜索) patients.
Dr. Jorge Nieva from the University of Southern California emphasized that determining optimal drug partnerships with TKIs is natural, especially as ADCs offer advantages through continuous tumor cell exposure and improved pharmacokinetics compared to traditional chemotherapy delivery. For patients developing TKI resistance, cytoreductive strategies including ADCs could help prolong time to resistance progression.
Future Directions in Precision Oncology
ADCs represent a dynamic and rapidly advancing therapeutic class that bridges targeted antibody precision with cytotoxic payload potency. The approvals of multiple ADCs illustrate how these agents are reshaping treatment paradigms for both biomarker-selected and biomarker-agnostic patient populations.
However, setbacks in late-phase trials, such as the discontinued HERTHENA-Lung02 study of patritumab deruxtecan which failed to demonstrate overall survival benefit, emphasize that continued refinement is needed. These mixed results highlight both the promise and hurdles in successfully translating ADCs from early-phase studies into clinical practice.
With ongoing clinical trials and technological innovation, ADCs are positioned to become essential tools in NSCLC (搜索) treatment and key drivers in precision oncology evolution. The technology's continued development promises to expand treatment options for patients across diverse molecular subtypes and resistance patterns.